NCT00715689View on ClinicalTrials.gov

Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Growth Hormone DisorderAdult Growth Hormone Deficiency
Interventions
DRUG

NNC126-0083

Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks

DRUG

NNC126-0083

Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks

DRUG

NNC126-0083

Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks

DRUG

NNC126-0083

Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks

DRUG

placebo

Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks

DRUG

placebo

Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks

DRUG

placebo

Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks

DRUG

placebo

Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks

Trial Locations (3)

2100

Novo Nordisk Investigational Site, København Ø

5000

Novo Nordisk Investigational Site, Odense

8000

Novo Nordisk Investigational Site, Århus C

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY